A weight management service for Nigerians that takes the medicine seriously, treats patients like adults, and doesn't cut corners on cold chain.
Tirzepatide — the most effective GLP-1 medication in clinical trials — was available in the US and Europe but not accessible in Nigeria. The people who needed it most were left with diets that don't work and supplements that do nothing.
Even when people sourced GLP-1 medications privately, they arrived warm. Tirzepatide degrades outside 2–8°C. A warm pen is an expensive placebo. Nobody was solving the last-mile cold chain problem for Nigerian consumers.
People were self-prescribing doses, skipping the manufacturer's titration ladder, and dealing with severe nausea because nobody told them to start at 2.5mg. The medication works, but only if you use it correctly.
We built the service that solves all three: branded Tirzepatide from a verified manufacturer, delivered cold to your door, with a care team that reviews your health before your first dose and supports you through treatment.
Second Cure is a treatment service built by people who were frustrated by the gap between what GLP-1 medications can do and how they're actually accessed in Nigeria. We're not a pharmacy. We're not a hospital. We're the infrastructure that connects you to effective treatment safely.
Tirzepatide must stay between 2–8°C. We refrigerate from the moment stock arrives at our facility through to your doorstep. If a package goes warm, we don't send it. Full stop.
We supply Tizaro (Tirzepatide) by Ziska Pharmaceuticals — a branded, batch-verified product. No compounded copies, no grey-market alternatives, no cutting corners on the thing that goes into your body.
Everyone starts at 2.5mg. Not because we're being cautious for the sake of it, but because the manufacturer's dose ladder exists for a reason: it reduces nausea and lets your body adjust before increasing the effect.
We review your health before approving treatment, we deliver medication safely, and we support you through the process. If something in your assessment concerns us, we'll tell you directly rather than approve an order we shouldn't.
Second Cure is operated by Second Cure Labs Ltd from Lagos, Nigeria. We source, store, review, and deliver from within the country — not from a warehouse in Europe hoping it arrives cold.
We started this because we wanted access to Tirzepatide ourselves and couldn't find a trustworthy way to get it in Nigeria. Every decision we make comes from that frustration.
We sell one medication: Tirzepatide. We don't try to be a general pharmacy or a wellness brand. We do one thing — GLP-1 treatment — and we do it properly: cold chain, batch verified, care team reviewed.
People in Nigeria are already buying GLP-1 medications through informal channels. Here's why that's risky and what we do differently.
We think you deserve to know exactly what you're signing up for. Here's the honest version.
We source Tirzepatide, review your health information, deliver the medication cold, and support you through treatment. That's our scope and we're good at it.
If your assessment reveals something that needs in-person medical attention, we'll tell you. We won't approve an order just to make a sale.
Tirzepatide works — the clinical data is clear. But it works best when combined with smaller meals, regular movement, and realistic expectations. We'll be honest about that.
This isn't a UK or US service repackaged for Africa. We're based in Lagos, we understand the food, the lifestyle, and the culture. Our learn articles cover jollof, pounded yam, and chin chin — not kale smoothies.
Nigeria has one of the fastest-growing obesity rates in Sub-Saharan Africa. The conversation about weight is changing — from "big is beautiful" to recognising the health risks of carrying excess weight: diabetes, hypertension, joint pain, sleep apnoea. But the solutions available haven't kept up.
Tirzepatide (a dual GIP/GLP-1 receptor agonist) showed 22.5% average body weight reduction in the SURMOUNT-1 trial — the largest weight loss ever recorded in a randomised clinical trial. It's available in the US, UK, Europe, and parts of Asia. Until now, Nigerians who wanted access had to import it privately, with no cold chain and no health screening.
We exist to close that gap. Not by being the cheapest option — ₦275,000 is a serious investment — but by being the only option that does it properly.
Complete your health questionnaire in 3–5 minutes. Your care team will review it within 24 hours and confirm whether treatment is right for you.